Skip to NavigationSkip to content

Features

A GP's view on how the use of opinion leaders by pharma should be handled

An agency's view on managing opinion leader relationships

Usability, usability, usability. It's a new mantra you will be hearing more of in the coming months. But is it just another piece of jargon you...

Increasing blockbuster patent expiries combined with geographic market expansion will fuel healthy growth in the cancer generics market.

IMS data suggest that by the end of 2002, 20% of all UK prescriptions dispensed will be parallel imports. Pharmafocus investigates one of pharma's...

Now that the storm of Whitehall-led NHS reform appears to be abating, the long journey towards the ultimate aim of all the re-organisation has...

What do recent rulings mean for pharmaceutical companies that want to increase the trademark protection on their products?

How far can healthcare copywriters keep within established rules and still ensure that they are really saying something to their target audience...

Can pharma ever embrace new marketing ideas?

Even in the best of circumstances, a drug spends 10 to 12 years of its 20-year patent life being tested and proven. So is the clinical trial a...